
Novartis (NVS) Stock Forecast & Price Target
Novartis (NVS) Analyst Ratings
Bulls say
Novartis demonstrates a robust outlook supported by the strong performance of its key drug Cosentyx, which achieved 25% year-over-year growth due to successful label expansions and market uptake. The firm has raised its 2024 financial outlook, indicating positive sales trends across multiple therapeutic areas, with potential for further growth stemming from unmodeled pipeline assets that may prove clinically effective. Additionally, the long lifecycle and targeted approach of Scemblix, alongside the promising revenue potential from other therapies, position Novartis favorably for continued financial success.
Bears say
The negative outlook on Novartis's stock is influenced by concerns regarding the clinical viability of its late-stage assets, which, if proven unviable, could exert downward pressure on share prices. Furthermore, any shortfalls in sales relative to projections or consensus estimates may lead to additional negative impacts on stock value. Additionally, potential delays or rejections in the approval process for new pipeline assets and label-expanding initiatives could adversely affect future cash flow and overall valuation, compounded by external factors such as unfavorable policy developments or economic downturns.
This aggregate rating is based on analysts' research of Novartis and is not a guaranteed prediction by Public.com or investment advice.
Novartis (NVS) Analyst Forecast & Price Prediction
Start investing in Novartis (NVS)
Order type
Buy in
Order amount
Est. shares
0 shares